Skip to main content

Advertisement

Table 2 Risk factors and treatment outcome of patients with candidemia in Teaching Hospital Kandy

From: The emergence of non-albicans candidemia and evaluation of HiChrome Candida differential agar and VITEK2 YST® platform for differentiation of Candida bloodstream isolates in teaching hospital Kandy, Sri Lanka

  Candidemia (n = 110)  
Parameters C. albicans (n = 34) Non albicans (n = 76) Odds ratio confident interval (95%) and P value
Age > 0.05
Gender male: female 1.2:0.8 1.3:0.7 > 0.05
Clinical risk factors
 Diabetes 26 (23.6%) 19 (25%) > 0.05
 Liver failure 12 (11%) 19 (25%) > 0.05
 Chronic lung diseases 15 (13.6%) 16 (21%) > 0.05
 Renal failure 12 (35.2%) 18 (24.3%) > 0.05
 Solid organ malignancy 7 (20.6%) 12 (16.2%) > 0.05
 Hematological malignancies 6 (17.6%) 16 (21%) > 0.05
 Exposure of broad spectrum antibiotics 28 (82.3%) 56 (73.7%) > 0.05
 Exposure of anti-fungal 3 (8.8%) 38 (50%) 2.2 (1.9–3.2); 0.03
 Under gone abdominal surgeries 7 (20.6%) 19 (25%) > 0.05
 On immune suppressive medications 6 (17.6%) 38 (50%) 2.4 (2.1–2.9); 0.04
 On hemodialysis 12 (35.2%) 22 (29.7%) > 0.05
 Prolonged intensive care stay ≥14 days 8 (23.5%) 56 (73.7%) 3.3 (2.2–4.5); 0.03
 On central venous line > 8 days 16 (47.0%) 64 (84.2%) 4.3 (3.4–5.4); 0.03
 On urinary catheters > 10 days 18 (52.9%) 38 (50%) > 0.05
Mechanical ventilation
 Presence of prosthesis or implant 12 (35.5%) 26 (35.5%0 > 0.05
 Total parenteral nutrition 6 (17.6%) 16 (21%) > 0.05
 Candiduria 6 (17.6%) 16 (21%) > 0.05
6 (17.6%) 12 (15.7%) > 0.05
Duration of treatment 16.8 ± 2.2 days 26.8 ± 2.2 days 0.03
Out come
 Complete recovery 28 (82.3%) 48 (63.1%) 0.04
 Death 6 (17.7%) 28 (36.9%) 0.04
 Day 7 2 (33.3%) 18 (64.2%) 0.03
 Day 30 4 (66.6%) 10 (35.8%) 0.04
  1. P < 0.05 taken as significant